N
86.74
-4.95 (-5.39%)
| Previous Close | 91.68 |
| Open | 91.87 |
| Volume | 1,524,641 |
| Avg. Volume (3M) | 1,271,096 |
| Market Cap | 2,880,665,088 |
| Price / Sales | 22.06 |
| Price / Book | 23.06 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -152.49% |
| Operating Margin (TTM) | -424.15% |
| Diluted EPS (TTM) | -9.45 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Total Debt/Equity (MRQ) | 1,358.71% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | -176.87 M |
| Levered Free Cash Flow (TTM) | -47.84 M |
| Return on Assets (TTM) | -26.80% |
| Return on Equity (TTM) | -189.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Nektar Therapeutics | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 67.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bvf Inc/Il | 31 Dec 2025 | 1,559,595 |
| Two Seas Capital Lp | 31 Dec 2025 | 745,185 |
| Prosight Management, Lp | 31 Dec 2025 | 554,633 |
| Sofinnova Investments, Inc. | 31 Dec 2025 | 438,630 |
| Emerald Advisers, Llc | 31 Dec 2025 | 384,342 |
| 22Nw, Lp | 31 Dec 2025 | 331,115 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 165.00 (HC Wainwright & Co., 90.24%) | Buy |
| Median | 151.00 (74.09%) | |
| Low | 150.00 (B. Riley Securities, 72.94%) | Buy |
| Average | 155.33 (79.09%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 61.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 23 Feb 2026 | 150.00 (72.94%) | Buy | 73.62 |
| BTIG | 10 Feb 2026 | 151.00 (74.09%) | Buy | 56.00 |
| 29 Jan 2026 | 118.00 (36.05%) | Buy | 35.23 | |
| HC Wainwright & Co. | 10 Feb 2026 | 165.00 (90.23%) | Buy | 56.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Jan 2026 | Announcement | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |